Literature DB >> 18628402

Structural motifs of importance for the constitutive activity of the orphan 7TM receptor EBI2: analysis of receptor activation in the absence of an agonist.

Tau Benned-Jensen1, Mette M Rosenkilde.   

Abstract

The Epstein-Barr induced receptor 2 (EBI2) is a lymphocyte-expressed orphan seven transmembrane-spanning (7TM) receptor that signals constitutively through Galphai, as shown, for instance by guanosine 5'-O-(3-thio)triphosphate incorporation. Two regions of importance for the constitutive activity were identified by a systematic mutational analysis of 29 residues in EBI2. The cAMP response element-binding protein transcription factor was used as a measure of receptor activity and was correlated to the receptor surface expression. PheVI:13 (Phe257), and the neighboring CysVI:12 (Cys256), in the conserved CW/FxP motif in TM 6, acted as negative regulators as Ala substitutions at these positions increased the constitutive activity 5.7- and 2.3-fold, respectively, compared with EBI2 wild type (wt). In contrast, ArgII:20 (Arg87) in TM-2 acted as a positive regulator, as substitution to Ala, but not to Lys, decreased the constitutive activity more than 7-fold compared with wt EBI2. IleIII:03 (Ile106) is located only 4 A from ArgII:20, and a favorable electrostatic interaction with ArgII:20 was created by introduction of Glu in III:03, given that the activity increased to 4.4-fold of that wt EBI2. It is noteworthy that swapping these charges by introduction of Glu in II:20 and Arg in III:03 resulted in a 2.7-fold increase compared with wt EBI2, thereby rescuing the two signaling-deficient single mutations, which exhibited a 3.8- to 4.5-fold decrease in constitutive activity. The uncovering of these molecular mechanisms for EBI2 activation is important from a drug development point of view, in that it may facilitate the rational design and development of small-molecule inverse agonists against EBI2 of putative importance as antiviral- or immune modulatory therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18628402     DOI: 10.1124/mol.108.049676

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

1.  hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.

Authors:  Richard W Mercier; Ying Pei; Lakshmipathi Pandarinathan; David R Janero; Jing Zhang; Alexandros Makriyannis
Journal:  Chem Biol       Date:  2010-10-29

2.  Ligand modulation of the Epstein-Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonist.

Authors:  Tau Benned-Jensen; Christopher Smethurst; Peter J Holst; Kevin R Page; Howard Sauls; Bjørn Sivertsen; Thue W Schwartz; Andy Blanchard; Robert Jepras; Mette M Rosenkilde
Journal:  J Biol Chem       Date:  2011-06-14       Impact factor: 5.157

3.  Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2.

Authors:  P C Jensen; S Thiele; A Steen; A Elder; R Kolbeck; S Ghosh; T M Frimurer; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization.

Authors:  C Taylor Gilliland; Catherina L Salanga; Tetsuya Kawamura; JoAnn Trejo; Tracy M Handel
Journal:  J Biol Chem       Date:  2013-09-20       Impact factor: 5.157

5.  Biased agonism and allosteric modulation of G protein-coupled receptor 183 - a 7TM receptor also known as Epstein-Barr virus-induced gene 2.

Authors:  Viktorija Daugvilaite; Christian Medom Madsen; Michael Lückmann; Clara Castello Echeverria; Andreas Walter Sailer; Thomas Michael Frimurer; Mette Marie Rosenkilde; Tau Benned-Jensen
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

6.  An angiotensin II type 1 receptor activation switch patch revealed through evolutionary trace analysis.

Authors:  Marie Mi Bonde; Rong Yao; Jian-Nong Ma; Srinivasan Madabushi; Stig Haunsø; Ethan S Burstein; Jennifer L Whistler; Søren P Sheikh; Olivier Lichtarge; Jakob Lerche Hansen
Journal:  Biochem Pharmacol       Date:  2010-03-21       Impact factor: 5.858

7.  Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms.

Authors:  Marie Mi Bonde; Jonas Tind Hansen; Samra Joke Sanni; Stig Haunsø; Steen Gammeltoft; Christina Lyngsø; Jakob Lerche Hansen
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

8.  Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants.

Authors:  T Benned-Jensen; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2010-02-08       Impact factor: 8.739

9.  Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.

Authors:  S Thiele; J Mungalpara; A Steen; M M Rosenkilde; J Våbenø
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

10.  Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial.

Authors:  Sarah Ekeloef; Natalie Halladin; Siv Fonnes; Svend Eggert Jensen; Tomas Zaremba; Jacob Rosenberg; Grete Jonsson; Jens Aarøe; Lærke Smidt Gasbjerg; Mette Marie Rosenkilde; Ismail Gögenur
Journal:  J Cardiovasc Transl Res       Date:  2017-10-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.